Cochrane · systematic review · CD010177
Long‐acting beta₂‐agonists for chronic obstructive pulmonary disease
Kew, KM, Mavergames, C, Walters, JAE · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
7
No studies
1
Included studies
NR
No studies 1 · 12.5%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 12.5%Moderate 6 · 75%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Long‐acting beta2‐agonists compared with placebo for chronic obstructive pulmonary disease
Population: people with chronic obstructive pulmonary disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes Long‐acting beta2‐agonists vs placebo | no estimate extracted | NR | No studies |
Quality of life1 St George's Respiratory Questionnaire (SGRQ); lower scores are better 16 months Long‐acting beta2‐agonists vs placebo | no estimate extracted | 17 studies · 11397 participants | Moderate Downgraded: imprecision, inconsistency, publication bias |
Severe exacerbations (hospitalisations) Long‐acting beta2‐agonists vs placebo | OR 0.73 [0.56, 0.95] | 7 studies · 2859 participants | Moderate Downgraded: imprecision, inconsistency, publication bias |
Moderate exacerbations (course of antibiotics or oral steroids) Long‐acting beta2‐agonists vs placebo | OR 0.73 [0.61, 0.87] | 7 studies · 3375 participants | Moderate Downgraded: imprecision, inconsistency, publication bias |
Severe/moderate exacerbations (hospitalisation or course of medication or ER visit) Long‐acting beta2‐agonists vs placebo | OR 0.88 [0.76, 1.02] | 7 studies · 3968 participants | Moderate Downgraded: imprecision, inconsistency, publication bias |
Mortality (all‐cause) Long‐acting beta2‐agonists vs placebo | OR 0.9 [0.75, 1.08] | 23 studies · 14079 participants | Moderate Downgraded: imprecision, inconsistency, publication bias |
Participants with one or more serious adverse event (non‐fatal) Long‐acting beta2‐agonists vs placebo | OR 0.97 [0.83, 1.14] | 20 studies · 12446 participants | Moderate Downgraded: imprecision, inconsistency, publication bias |
Predose FEV1 (mL) Long‐acting beta2‐agonists vs placebo | MD 73 | 14 studies · 6125 participants | Low Downgraded: imprecision, inconsistency, publication bias |